explore -WSS

explore

author：comprehensive 2025-09-27 22:47:18 - browse：3

An eye emerges from lines of binary codes — health tech coverage from STAT — Adobe

Investors are starting to back startups that offer privacy and security services to bolster health AI products already on the market while they wait for crucial safety and privacy regulations to take shape.

Though health leaders are racing to deploy generative AI products that can automatically transcribe doctor-patient conversations during medical appointments or churn through massive repositories of scientific research, they’re still flummoxed about how to measure their quality. Cybersecurity experts have warned that indiscriminately hooking third-party apps up to health system networks could expose sensitive data to hackers as ransomware attacks surge, and regulators and industry groups are rushing to set standards for responsible AI use.

Several government agencies and industry groups are working on rules and recommendations for avoiding bias and safety hazards within medical AI, but hospitals and startups are still in the dark about what exactly those will require and who’ll eventually be liable for any harm caused. It could be months, or even years, before these overlapping rules from multiple federal agencies are in place, and those rules might still change as the technology evolves.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA approves first new drug developed for postpartum depression

WSS

Readout LOUD podcast: Live from the 2023 STAT Summit

Why a market frenzy over new weight loss drugs defies logic

Roche drug slashes death risk in early

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Timeline: Key moments in fight for gay rights

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Wikipedia

explore

focus

Drug repurposing or repositioning? The language matters

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Drug repurposing or repositioning? The language matters

Questions loom on AstraZeneca cancer drug as safety concerns ebb

United colonoscopy coverage change 'may cost lives,' doctors say

Results on Novartis prostate cancer therapy could expand its use

Moonlake's readout produced a cash windfall. Risks remain

Patients, doctors are clashing about side effects of hormonal birth control

The cancer drug shortage isn’t new — and neither are the solutions

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Wikipedia

Can medical device makers keep up in the race to treat obesity?

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

How AI can help patients find reliable information about doctors

STAT Summit: The economic case for universal basic health care

Altering the blood type of lungs raises potential for universal organs for transplants

STAT Summit: Ending the crisis of Black deaths in the U.S.

focus

knowledge

focus

hotspot